Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
General24 hours agoFerries and celebrities as pollies dash to win the west
-
General19 hours agoSikh Lane a WA first as Dongara puts multicultural history on the map
-
General23 hours agoJacinta Nampijinpa Price vows to ‘make Australia great again’, accuses media of being ‘Trump obsessed’
-
General22 hours agoBad raptor: vultures among world’s least loved animals